Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
News|Articles|September 1, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
- Volume 11
- Issue 9
CordenPharma in France Reports Successful FDA Inspection
Author(s)Pharmaceutical Technology Editors
The CordenPharma Chenôve, France manufacturing facility completed an FDA Inspection with no 483s reported.
Advertisement
CordenPharma announced on Aug. 31, 2016 that the CordenPharma Chenôve (France) manufacturing facility completed an FDA Inspection and received a successful response with no 483s reported. The previous FDA Inspection took place in 2014.
Yves Michon, Managing Director of CordenPharma Chenôve comments, “We are pleased with the outcome of the FDA Inspection in August 2016, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance while continuously improving our standards for our customers and their projects going forward.”
Source:
Articles in this issue
about 10 years ago
Putting Shelf-Life to the Testabout 10 years ago
The Enzymatic Catalysis Route to Going Greenabout 10 years ago
CMOs Step Up to Test New Bioprocessing Technologyabout 10 years ago
SGS Opens New Facility in Wiesbaden, Germanyabout 10 years ago
CSafe Acquires Kalliboxabout 10 years ago
Automated Infrared Microscope Effectively Analyzes Micro Samplesabout 10 years ago
Copley Scientific Launches Products for Tablet Dissolution Testingabout 10 years ago
Eppendorf Expands Single-Use Vessel Portfolioabout 10 years ago
PANalytical launches the Empyrean Nano editionabout 10 years ago
Fuji Health Changes Name to Fuji Chemical Industries USA, Inc.Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement